Skip to content
Medical Learning Institute Inc
Home
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
Menu Toggle
About MLI Accreditation
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Medical Learning Institute Inc
Main Menu
Home
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
Menu Toggle
About MLI Accreditation
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Part 2 | Wednesday, August 7, 2024
Please enable JavaScript in your browser to complete this form.
Please enable JavaScript in your browser to complete this form.
Please provide your National Provider Identifier (NPI) number
1. Mr. Jay is a 50-year-old, Caucasian patient with a BMI of 38 kg/m2, which is categorized as class II obesity. If his waist circumference is 122 cm (48 inches), what is his disease risk relative to normal weight and waist circumference?
*
A. Increased Risk
B. High Risk
C. Very High Risk
D. Extremely High Risk
2. To facilitate shared decision-making, what counseling and education points would you provide a patient regarding second-generation AOMs, allowing them to make an informed decision about their therapy?
*
A. GI adverse events are mild, but do not typically go away over time
B. They can only take second-generation AOMs for no more than three months
C. Obesity is a chronic disease; this therapy will help adjust your physiology while you take it
D. You don’t have to worry about your diet with these therapies, as they will naturally make you eat less
3. A second-generation AOM was initiated in your patient two weeks ago. They report that they have been experiencing some gastrointestinal issues. Which of the following is the best way to manage these common side effects?
*
A. Switch to glimepiride
B. Titrate dose slowly
C. Switch to semaglutide PO
D. Change to a shorter acting agent
Submit
Scroll to Top